Dermatology Therapeutics Drug Development Pipeline Review, 2016
Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established and generic products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.
There are over 800 products in active development in the dermatology therapy area, with the majority of products being small molecules. Biologics represent approximately 40% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.
Overall, the dermatology pipeline is highly innovative, owing to the advancements in the understanding of the disease pathways of many skin disorders. The number of strong late-stage products and substantial early-stage segment of this active and diverse pipeline are strong indicators of long-term growth in this market.
The report provides comprehensive information on the pipeline development landscape for is Acne vulgaris, Psoriasis and Atopic dermatitis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.
- Which companies are the most active within the pipeline for dermatology? - Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? - To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? - What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication - Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each - Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these - Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Our reports have been used by over 10K customers, including:
Pruritus Global Clinical Trials Review, H1, 2020 Summary This clinical trial report, “Pruritus Global Clinical Trials Review, H1, 2020" provides an overview of Pruritus Clinical trials scenario.This report provides top line data relating to the clinical trials on Pruritus. Report includes...
Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H1 2020, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape. Cancer...
Retinoic Acid Receptor Alpha - Pipeline Review, H1 2020 Summary Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Retinoic acid receptor alpha (RARA) is a nuclear receptor that is encoded by the RARA gene. RARA plays an essential role in...
Retinoic Acid Receptor Gamma - Pipeline Review, H1 2020 Summary According to the recently published report ’Retinoic Acid Receptor Gamma - Pipeline Review, H1 2020’; Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes...